3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
7
Triple Negative Breast Neoplasms
5
Lung Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasm Metastasis
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Neoplasms
1
Metastatic Pancreatic Ductal Adenocarcinoma
1
Melanoma, Cutaneous Malignant
1
Head and Neck Neoplasms
1
GastroEsophageal Cancer
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Pancreatic Ductal
1
CLDN18.2 Positive
1
Anal Cancer Metastatic
1
Adenocarcinoma
1
Interventions
trifluridine tipiracil drug combination
1
reolysin
1
atezolizumab
1
Gemcitabine
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anal Cancer Metastatic
×
Albumin-Bound Paclitaxel
×
30 days
×
Clear all
NCT07280377
2026-05-19
GOBLET
Oncolytics Biotech
Phase 1/2
Active not recruiting
122 enrolled